Objective:

To explore the efficacy of a glutamatergic treatment protocol for trauma-related disorders using dextromethorphan (DXM) in combination with fluoxetine and bupropion, with optional piracetam.

Key Findings:

• Clinically meaningful symptom improvement was observed within days to weeks.
• Notable reductions in intrusive memories, rumination, somatic pain, and functional disability were reported.
• No episodes of dissociation, hypertension, or mania were documented during follow-up.

Interpretation:

The findings suggest that glutamatergic treatments may provide rapid relief for trauma-related symptoms, expanding the potential treatment framework beyond traditional monoaminergic medications.

Limitations:

• The study is based on a small case series and lacks controlled investigation.
• Structured screening for hypomania/mania and serotonergic toxicity was not performed.

Conclusion:

Further controlled investigations into oral NMDA–AMPA modulators are warranted for trauma-related conditions, as these findings are hypothesis-generating.